Gland Pharma Ltd.
GLAND
Gland Pharma Ltd. Share Price
1,702.10 -3.90 (-0.23%)Fundamentals
Market Cap₹27,676Cr | EPS₹42.40 |
Book Value/Share₹596.28 | P/E Ratio (TTM)32.98 |
Industry P/E (TTM)37.97 | P/B Ratio3.05 |
Long Term D/E0.03 | ROE7.81% |
Dividend Yield (TTM)1.10% |
Analysis
Overview
Key stock indicators that show how well a company is doing, making it easier to understand its true value and performance.
Outperformer
Fairly Valued
Good Quality
Low Price Fluctuation
Analysts are Neutral
Peer Comparison
Peer comparison lists companies from the same sector, scored and ranked based on Crisp Analysis. It helps understand how a company stands against its competitors.
Shareholding Pattern
Shareholding pattern shows how a company’s shares (ownership) are distributed among different shareholding entities like promoters, Foreign Institutional Investors (FIIs), Domestic Institutional Investors (DIIs), and retail investors, among others. Changes in the shareholding pattern can indicate the performance outlook of a stock.
FAQs on Gland Pharma Ltd.
The share price of Gland Pharma Ltd. is ₹1,702.10 on NSE as of 2/4/2026, 12:54:47 pm. Share prices may change frequently due to market movements.
The market capitalisation of Gland Pharma Ltd. is ₹27,676Cr as of 2/4/2026, 12:54:47 pm
The current Price to Earnings (P/E) ratio of Gland Pharma Ltd. is 32.99 as of 2/4/2026, 12:54:47 pm
The Price to Book (P/B) ratio of Gland Pharma Ltd. stands at 3.05 as of 2/4/2026, 12:54:47 pm
Gland Pharma Ltd. reported an ROE of 7.82% for the last reported financial year on a consolidated account basis.
As of 2/4/2026, 12:54:47 pm, Gland Pharma Ltd.’s shareholding pattern is: promoters hold 51.80%, FIIs hold 7.60%, DIIs hold 1.60%, and public shareholders hold 7.60%.
The 52-week high of Gland Pharma Ltd. is ₹1,706.60 and the 52-week low is ₹1,652.00 as of 2/4/2026, 12:54:47 pm.
The earnings per share (EPS) of Gland Pharma Ltd. is ₹15.87 for the quarter ended Dec 2025.
The stock symbol of Gland Pharma Ltd. is GLAND.
You can buy Gland Pharma Ltd. shares by opening a demat and trading account with Share.Market and placing a buy order on NSE or BSE during market hours.
The fair value of Gland Pharma Ltd. depends on factors such as earnings growth, financial performance, and overall market conditions. Investors should assess fundamentals before making investment decisions.
Earnings Per Share
Earnings per share (EPS) measures the profit earned by a company for each of its outstanding shares. Generally, the higher a company’s EPS is, the more profitable it is considered to be.
Income Statement
Also called a profit and loss statement, an income statement shows a company’s income, expenses, and how much profit or loss it has made over a specific accounting period. It provides a clear view of how well the business is running.
| Particulars (in Cr) | Dec 2025 | Q/Q Change |
|---|---|---|
| Operating Revenue | 1,695.36 | +14.02% |
| Other Income | 63.17 | -24.94% |
| Total Income | 1,758.54 | +11.93% |
| Total Expenditure | 1,260.49 | +7.46% |
| EBIDT | 473.70 | +19.01% |
| Depreciation | 107.64 | +1.25% |
| Interest | 3.93 | -49.74% |
| Tax | 100.65 | +0.42% |
| Net Profit | 261.48 | +42.36% |
Balance Sheet
A balance sheet is a financial statement that details a company’s assets, liabilities, and shareholders’ equity at a given time. It helps assess how financially strong and stable the company is.
| Particulars (in Cr) | Mar 2025 |
|---|---|
| Total Current Assets | 6,782.94 |
| Total Non-Current Assets | 4,441.98 |
| Fixed assets | 4,049.60 |
| Total Assets | 11,224.92 |
| Total Current liabilities | 1,564.84 |
| Total Non Current Liabilities | 509.33 |
| Total Equity Plus Liabilities | 11,224.92 |
| Total Shareholder Funds | 9,150.74 |
| Total Debt to Equity | 3.00% |
Cash Flow
Cash flow highlights the cash or cash equivalents moving in and out of a company during a particular period. It provides a clear picture of how well a company manages its cash by tracking its operating, investing and financing activities.
| Particulars (in Cr) | Mar 2025 |
|---|---|
| Cash from Operating Activity | 914.73 |
| Cash from Financing Activities | -433.48 |
| Cash from Investing Activities | 1,704.74 |
| Net Cash Flow | 2,185.99 |
Time Period: Daily
SMA/EMA (Moving Average) Analysis
Bullish Moving Averages2
Bearish Moving Averages14
5 Day
1,701.4010 Day
1,664.2020 Day
1,672.2030 Day
1,724.6050 Day
1,753.00100 Day
1,746.20150 Day
1,811.60200 Day
1,833.90Indicators
RSI (14)
50.38MACD (12, 26)
-20.10MACD Signal Line (9)
-31.57MFI (14)
52.22ATR (14)
58.88ADX (14)
20.79ROC (21)
-8.34ROC (125)
-12.87Pivot Analysis
Pivot analysis uses a special price point, called the pivot point, to show the overall market trend during different periods. This pivot point is the average of the previous day’s high, low, and closing prices of a specific asset.
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 1,730.60 | 1,755.20 | 1,775.40 | 1,710.40 | 1,685.80 | 1,665.60 | 1,641.00 |
Note: Support and Resistance level for the day, calculated based on price range of the previous trading day.
Volume Analysis
Volume analysis tracks how many shares were traded for a specific period. Total traded volume represents the overall number of shares traded, while combined delivery volume indicates only those shares which are delivered (transferred for ownership). Delivered shares indicate long-term investor interest.
Gland Pharma Ltd.
GLAND
Open Price | 1,686.00 |
Prev Close | 1,706.00 |
Upper Circuit | 2,047.20 |
Lower Circuit | 1,364.80 |
Volume | 45,306 |
Average Traded Price | 1,676.29 |